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Abstract
Acromegaly is a rare disease caused by the secretion of growth hormone (GH) in excess, in most cases from a pituitary tumour. The diagnosis 
is usually delayed and is often associated with the development of various complications causing premature mortality. In patients with 
hypertension, heart failure, diabetes, and arthropathy that is non-specific for age, attention should be paid to the occurrence of somatic 
signs of acromegaly. As a screening test, insulin-like growth factor-1 (IGF-1) concentration should be assessed. Further diagnostic and 
treatment procedures are possible in specialised centres. The first-line therapy is selective transsphenoidal adenomectomy. Patients with 
a good prognosis related to a surgical removal of the pituitary tumour should be referred only to centres experienced in performing this 
type of procedure, after pharmacological preparation. Other patients, and those who have not recovered after surgical treatment, should 
be subjected to long-term pharmacotherapy with long-acting somatostatin analogues. In each case, the complications of acromegaly 
should be followed-up long-term and actively treated. This proposed new recommendation should be helpful for the management of 
patients with acromegaly. (Endokrynol Pol 2014; 65 (4): 326–331)
Key words: acromegaly; diagnosis; therapy; guidelines
Streszczenie
Akromegalia jest rzadką chorobą spowodowaną nadmiernym wydzielaniem hormonu wzrostu (GH), zwykle przez guz przysadki. Roz-
poznanie jest opóźnione i często związane z rozwojem różnych powikłań powodujących zwiększone zagrożenie zgonem. U chorych 
z nadciśnieniem, niewydolnością serca, cukrzycą, artropatiami, nietypowymi do wieku należy zwrócić uwagę na występowanie objawów 
akromegalii. Jako badanie przesiewowe należy wykonać oznaczenie stężenia insulinopodobnego czynnika wzrostu-1 (IGF-1). Dalsza dia-
gnostyka i leczenie powinny być prowadzone w wyspecjalizowanych ośrodkach. Leczeniem pierwszego rzutu jest wybiórcze usunięcie 
gruczolaka przysadki z dostępu przez zatokę klinową. Pacjenci rokujący wyleczenie operacyjnym usunięciem guza przysadki powinni 
być kierowani do ośrodków z doświadczeniem w tego typu zabiegach, po przygotowaniu farmakologicznym. Pozostali chorzy oraz ci po 
nieskutecznym leczeniu neurochirurgicznym powinni być długotrwale leczeni analogami somatostatyny. W każdym przypadku następ-
stwa akromegalii winny być przez całe życie monitorowane i aktywnie leczone. Proponowane nowe zalecenia powinny być pomocne 
w postępowaniu z pacjentami chorymi na akromegalię. (Endokrynol Pol 2014; 65 (4): 326–331)
Słowa kluczowe: akromegalia; diagnostyka; leczenie; zalecenia
Introduction
The symptoms of acromegaly had already been de-
scribed by the end of the 19th century; surgical treatment 
of somatotroph tumours has been performed since the 
beginning of the 20th century, and pharmacological 
treatment using somatostatin analogues for 25 years. 
In recent years, some of the diagnostic and treatment 
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criteria have changed [1, 2]. New registration provi-
sions concerning the administration of long-acting 
somatostatin analogues used in acromegaly have also 
been introduced. The way of perceiving patients with 
this chronic disease is also expanding, with more focus 
on the systemic complications that contribute to the 
decreased survival and reduced quality of life [3, 4].
Therefore, we present the current recommenda-
tions on diagnostic and therapeutic procedures in 
acromegaly, including national conditions.
Characteristics of the disease
Acromegaly is a rare chronic disease caused by the over-
production of growth hormone (GH), in most cases by 
a pituitary tumour. It leads to changes in appearance, 
including acral enlargement (hands, feet and face), 
hypertrophy of soft tissues, bones and internal organs 
and many systemic complications adversely affecting 
the quality of life and decreasing patient survival [5–7]. 
The symptoms of acromegaly are presented in Table I.
Epidemiology
The prevalence of acromegaly is approximately 70 
per one million inhabitants. Annually, there are ap-
proximately 3–4 newly diagnosed cases of the disease 
per million. Acromegaly is diagnosed with a similar 
frequency in both genders and most commonly in 
patients in their 30s and 40s. The disease is usually 
diagnosed about 5–10 years after the onset of the first 
symptoms, usually earlier in women than in men [5–9]. 
Detailed population studies conducted in recent years 
suggest significantly greater prevalence of acromegaly 
than previously thought [10]. Therefore, the disease 
should be actively searched for, particularly in males 
and subjects with cardiovascular and osteoarticular 
system disorders that are non-specific for age. Early 
diagnosis allows for surgical cure of the disease, giving 
a chance to restore life expectancy comparable to that 
of the normal population and improve quality of life.
Pathogenesis
Pituitary tumours secreting GH, which are the cause 
of acromegaly, are benign adenomas. At the diagnosis 
of the disease, their diameter usually exceeds 10 mm, 
so these are already macroadenomas which may lead 
to visual field defects and other endocrine disorders 
(hypopituitarism, hyperprolactinemia). Most of the 
symptoms and complications of the disease (Table II) 
result from an excessive effect of insulin-like growth fac-
tor 1 (IGF-1) on tissues, which is stimulated by increased 
GH secretion [5, 6]. As a rule, the exacerbation of clinical 
symptoms, systemic complications and concentration 
of GH positively correlate with the tumour size and 
the persistence of acromegaly. A longer duration of 
the undetected and untreated disease promotes the 
intensity of clinical symptoms, and the development of 
metabolic effects and systemic complications, and thus 
reduces the chances of a complete recovery.
Diagnosis
The diagnosis of active acromegaly is based on clinical 
symptoms (Table I) and a demonstrated simultane-
ous increase in IGF-1 and GH secretion. Patients with 
clinical symptoms indicating acromegaly should un-
dergo a screening test for IGF-1 concentration (Fig. 1). 
If IGF-1 values are increased (for age and sex), it is 
recommended to perform an oral glucose tolerance 
test (OGTT) after administration of 75 g of glucose. In 
patients with diagnosed diabetes mellitus, instead of 
OGTT, GH concentration should be tested several times, 
i.e. every 30 minutes for 2–3 hours. Active acromegaly 
is confirmed by an increased IGF-1 concentration and 
Table I. Symptoms of acromegaly
Tabela I. Objawy akromegalii
General 
symptoms
Enlargement of: hands, feet, facial bones (nose, 
mandible, frontal sinuses), tongue 
Thickened facial features 
Soft tissue swelling 
Enlargement of internal organs (visceromegaly) 
Weight gain 
Increased sweating 
Hirsutism 
Change in voice tone
Circulatory 
system
Arterial hypertension 
Dyspnoea, swelling (heart failure) 
Cardiac dysrhythmia
Respiratory 
system
Obstructive sleep apnoea, snoring 
Impaired patency of the upper respiratory tract
Endocrine 
system
Glucose intolerance, diabetes mellitus 
Goitre, thyroid dysfunction 
Galactorrhoea 
Possible tumours of other glands (MEN syndrome)
Digestive 
system
Constipation, possible elongation and widening of the 
colon (megacolon) 
Abdominal pain, blood in faeces (polyps and colonic 
diverticula)
Genitourinary 
system
Menstrual disorders 
Reduced libido 
Erectile dysfunction (hypogonadism) 
Renal colic (hypercalciuria, hyperparathyroidism — MEN)
Nervous 
system
Headache 
Visual field impairment (macroadenoma may compress 
the optic chiasm) 
Paresthesias, pareses (carpal tunnel syndrome)
Osteoarticular 
system
Bone and joint pain and deformities 
Limited joint mobility
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no suppression of GH secretion below 0.4 µg/L (ng/mL) 
in OGTT. Random GH level below 1.0 µg/L allows the 
exclusion of active acromegaly [2, 11, 12]. At the diag-
nosis of the disease, it is also necessary to evaluate the 
presence and degree of its systemic complications and 
metabolic disorders (Table II).
An unequivocal determination of the cause of 
acromegaly requires a contrast-enhanced magnetic 
resonance imaging (MRI) scan of the pituitary. In the 
case of diagnosing a pituitary macroadenoma, visual 
field should be evaluated. When the MRI examination 
does not reveal a pituitary tumour, there is a suspicion 
of growth hormone releasing hormone (GHRH) ectopic 
secretion, or less often GH secretion by neuroendocrine 
tumour, usually in the bronchi, thymus or pancreas [13].
An early diagnosis of acromegaly (usually a smaller 
tumour, less advanced clinical symptoms and compli-
cations) increases the efficacy of surgical and pharma-
cological treatment, reduces medical care costs, and 
potentially prevents premature mortality in patients 
with acromegaly.
Disease management
The basic goal of acromegaly treatment is the nor-
malisation of GH secretion which is associated with 
the restoration of life expectancy and improvement of 
the quality of life of patients. The secondary aim is to 
remove or significantly reduce the mass of the pituitary 
tumour which should result in an improvement of 
disorders associated with its expansion. Both objectives 
can be achieved by surgical and pharmacological treat-
ment, and, less frequently, radiotherapy [6, 11, 13, 14].
The therapy choice should be based on an evalu-
ation of possible complications and take into account 
the patient’s condition and willingness to undergo 
surgery. The basic treatment method of acromegaly, 
which may result in a recovery, is a surgical, selective 
adenomectomy using the transsphenoidal approach, if 
possible, while maintaining hormonal function of the 
residual pituitary gland. In the case of an extrapituitary 
source of the disease, the removal of neuroendocrine 
tumour ectopically secreting GHRH is advised. The 
efficacy and success of the surgical treatment of GH-
secreting tumours depends on: GH concentration, the 
size, location and expansion of the tumour, and the 
surgeon’s experience. In the case of microadenomas, 
surgical success (random GH concentration < 1.0 µg/L) 
is achieved in about 70-90% of patients, but in the case 
of macroadenomas the figure is only about 30–50% [13].
Thus, the bigger the tumour, with extrasellar expan-
sion, the lower the efficacy of neurosurgical treatment. 
Therefore, according to the recommendations of the Polish 
Society of Endocrinology, one should consider the need for 
the pre-surgical use of long-acting somatostatin analogues 
which facilitate surgical treatment by reducing the volume 
and changing the consistency of the pituitary tumour as 
well as by ensuring the clinical improvement of patients 
[15]. This treatment results in reduced swelling of soft 
tissues (easier intubation), and improved cardiovascular 
functions (decreased blood pressure and reduced degree 
of heart failure), obstructive sleep apnoea and parameters 
of metabolic disorders [16]. Better outcomes of surgical 
treatment are achieved in centres where an experienced 
neurosurgeon performs at least 50 transsphenoidal sur-
geries a year [13, 17]. Therefore, appropriately prepared 
patients should be referred for surgical treatment to cen-
tres specialising in pituitary surgery.
Since the majority of tumours observed at the 
diagnosis of acromegaly are macroadenomas, for 
a large proportion of patients surgical treatment does 
not ensure a complete cure. So it is recommended to 
use pharmacotherapy or, less often, radiotherapy. The 
removal of over 75% of the tumour mass increases the 
efficacy of postoperative treatment with somatostatin 
analogues [18]. An alternative or supplement to surgi-
cal treatment of GH-secreting pituitary adenomas is 
pharmacotherapy. These adenomas show the expres-
Table II. Complications in acromegaly
Tabela II. Powikłania akromegalii
Cardiovascular 
diseases
Hypertension (up to 60%) 
Cardiac hypertrophy (up to 90%) 
Cardiac dysrhythmia (up to 40%) 
Heart valve defects (up to 80%) 
Heart failure (up to 10%) 
Ischaemic heart disease (up to 40%) 
Sudden cardiac death 
Cerebral stroke
Respiratory 
diseases
Obstructive sleep apnoea (up to 80%) 
Obturation of the upper respiratory tract 
Bronchiectasis 
Emphysema
Neoplasms Malignant — colon (2%), thyroid (5%), breast and 
prostate cancers 
Benign — thyroid tumours (up to 90%), colonic 
polyps, uterine fibroids, benign prostatic hyperplasia
Metabolic and 
hormonal 
disorders
Hyperinsulinaemia (up to 80%) 
Prediabetes (up to 40%) 
Diabetes (up to 20%) 
Hyperlipidaemia 
Hypercalciuria (up to 70%) 
Hypogonadism (up to 50%) 
Hyperthyroidism (up to 15%)
Diseases of the 
osteoarticular 
system
Degenerative and proliferative changes (up to 70%) 
Reduced bone mineral density (osteoporosis) 
Vertebral fractures
Diseases of the 
nervous system
Visual field disturbances 
Neuropathies 
Carpal tunnel syndrome (up to 50%)
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sion of somatostatin receptors; therefore, the ligands 
of this receptor, somatostatin analogues (lanreotide 
and octreotide), normalise GH secretion in 60–75% of 
patients with acromegaly and significantly reduce the 
size of the pituitary tumour in about half of patients [6].
Currently, there are two long-acting somatostatin 
analogues used in Poland. Lanreotide autogel is avail-
able in 60, 90 and 120 mg ampoules, for subcutaneous 
administration every 28 days, with a possible extension 
of the interval between injections to 56 days for the 
dose of 120 mg [9, 19]. Octreotide LAR is manufac-
tured in 10, 20 and 30 mg ampoules, for intramuscular 
administration every 28 days, with a possible dose in-
crease to 40 mg every four weeks in patients for whom 
a 30 mg dose is inefficient [20]. The dose of somatostatin 
analogue should be adjusted to the clinical and labora-
tory effects obtained after three months of using the 
drug [13]. In terms of efficacy and tolerance, there are 
no fundamental differences between the above-men-
tioned preparations [21]. Treatment with them is safe 
and usually well tolerated. The most frequent adverse 
effects are: abdominal pain, loose stools or diarrhoea. 
Approximately 20% of treated patients may develop 
cholelithiasis, and rarely, pancreatitis [9].
As mentioned before, somatostatin analogues 
should be used for several months in preparation for 
the surgical treatment, and as a long-term therapy if 
surgical treatment has not been used or has proved 
ineffective. Treatment with somatostatin analogues 
should be the first-line therapy in patients with sig-
nificant contraindications or who refuse to undergo 
surgery and in patients with low chances of a cure or 
clinical improvement after the neurosurgical procedure 
(large tumours with extrasellar expansion without 
a significant pressure on optic nerves) [13].
Patients with active acromegaly after an inefficient 
surgical treatment of the pituitary adenoma or await-
ing the effects of radiotherapy should permanently 
receive long-acting somatostatin analogues in doses 
normalising the concentration of GH and IGF-1 as 
a complementary treatment [12–14]. The current pos-
sibility of using lanreotide autogel 120 mg less than once 
a month (even every 56 days) significantly may reduce 
treatment costs and increase the patient’s comfort and 
quality of life [9, 19, 22].
If the somatostatin analogue is inefficient, dopa-
mine agonist or GH-receptor antagonist (pegvisomant) 
should be added to the treatment (Fig. 1) [11, 14]. In 
some cases, GH-receptor antagonist may be used in 
monotherapy. The efficacy of dopamine agonists in 
the treatment of acromegaly is low. The recommended 
doses of these drugs in acromegaly should be higher 
than the doses used in the case of prolactin-secreting 
pituitary adenomas (prolactinoma) [13, 23].
Bromocriptine, which is easily available in Poland, 
normalises the concentration of IGF-1 only in 10% of 
patients with acromegaly. Cabergoline, which is much 
more expensive in Poland (no reimbursement), leads to 
the normalisation of IGF-1 in about 40% of cases and de-
creases GH secretion below 2 µg/L in 44% of patients with 
adenomas secreting only GH, and in 56% of patients with 
mixed tumours secreting both GH and PRL. Therefore, do-
pamine agonists may be used in the case of mixed tumours 
secreting GH and PRL and combined with somatostatin 
receptor ligands or GH receptor antagonist to improve 
their efficiency in patients showing resistance to maximal 
doses of somatostatin analogues [23, 24].
On the other hand, pegvisomant, which blocks GH 
action in target tissues in more than 90% of patients, 
normalises the concentration of IGF-1, thereby leading 
Figure 1. Diagnostics and treatment algorithm for acromegaly
Rycina 1. Algorytm diagnostyki i leczenia akromegalii
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to a clinical improvement and normalisation of metabolic 
disorders (i.e. it improves carbohydrate metabolism by 
increasing insulin sensitivity) [25]. Due to the systemic 
activity of the drug, GH concentration cannot be used to 
assess its efficacy. Pegvisomant does not reduce the size of 
the pituitary tumour, so it is necessary to control it during 
treatment using MRI. In the case of adenoma enlargement, 
additionally a somatostatin analogue may be used.
Because of the improving results of surgical treatment 
and the availability of efficient drugs, indications to use 
conventional radiotherapy in acromegaly have become 
controversial [26, 27]. Stereotactic radiotherapy should 
be considered only in the case of inefficient surgical and 
pharmacological treatment, bearing in mind that it leads 
to the normalisation of IGF-1 concentration within ten 
years in about 40% of patients and is associated with 
multiple complications. The most common of these is 
hypopituitarism (about 80% of patients who are subjected 
to conventional radiotherapy). Radial damage to optic 
nerves, as well as cerebral circulation disorders and the 
formation of secondary tumours are much less common.
The treatment of complications of acromegaly is an 
additional problem; these include mainly arterial hy-
pertension and heart failure, disorders of carbohydrate 
metabolism and degenerative and proliferative changes 
of the osteoarticular system (other complications are 
presented in Table II) [4]. These diseases not only lead to 
worsening of the quality of life and decreased survival 
of patients, but their treatment additionally generates 
significant costs. An early diagnosis of acromegaly cre-
ates an opportunity for its surgical treatment, which 
minimises the development of complications, thereby 
decreasing the costs of treatment.
Follow-up of patients
The efficacy of treatment and the course of the com-
plications should be controlled in each patient with 
acromegaly based on the clinical evaluation, as well 
as laboratory and imaging tests. The efficacy of surgi-
cal treatment can be evaluated by examining the GH 
concentration soon postoperatively (after one week), 
while a reliable assessment of the IGF-1 concentration 
should be carried out approximately three months after 
the surgery. The criterion of recovery is IGF-1 concen-
tration within reference values for age and sex, as well 
as GH level < 0.4 µg/L in OGTT [2]. If the efficiency 
of surgical treatment of acromegaly is confirmed in 
laboratory tests, and there are no clinical disorders of 
vision and pituitary function, there is no need for an 
MRI examination.
In patients who do not recover after surgery, im-
aging of the pituitary area using MRI should be per-
formed after 3–4 months, and in patients treated with 
the pharmacotherapy 6–12 months from its beginning. 
Further control MRI examinations should be repeated 
once a year (fast-growing tumours may be an excep-
tion). When evaluating the efficacy of pharmacological 
treatment, the clinical condition of the patient should 
be taken into account (together with an assessment of 
the visual field and the quality of life), as well as the 
results of basal IGF-1 (primarily), and random GH (ad-
ditionally) concentrations (there is no need to perform 
OGTT). It is assumed that an efficient pharmacological 
treatment (managing the course of the disease) is a treat-
ment which maintains the IGF-1 concentration within 
reference values for age and sex, and GH < 1.0 µg/L [2].
Clinically, complications (Table II) should be identified, 
actively monitored (Table III) and effectively treated in 
every patient with acromegaly. Taking into consideration 
the complications in the cardiovascular system, blood 
pressure should be measured during every examination 
of a patient with acromegaly, and ECG and echocardio-
graphic examinations should be performed once a year. 
Bearing in mind the most common complications in the 
respiratory system, it is recommended to perform a poly-
somnographic test. Due to common metabolic and hor-
monal complications, it is necessary to exclude disorders 
of glucose, lipids, calcium and phosphorus metabolism, 
as well as disorders of the thyroid and gonad functions. 
Due to the increased predisposition to tumourigenesis 
in acromegaly, it is first necessary to exclude proliferative 
Tabela III. Ocena przebiegu powikłań akromegalii
Table III. Evaluation of the course of complications in 
acromegaly
Examination Frequency of evaluation
Blood pressure Every 3–6 months, more frequently when 
treatment is changed
ECG Every year
Exercise ECG In the case of stenocardial symptoms
Echocardiography Every year
Polysomnography Every year
OGTT In the case of suspicion of diabetes mellitus
Fasting glucose Every 6–12 months
HbA1c Every 6–12 months in the case of diabetes
Lipid profile Every year
Ca, P In the case of symptoms of nephrolithiasis
TSH, fT4 Every year
PRL, testosterone (♂) Every year
PRL, LH, FSH, E2 (♀) Every year
Thyroid ultrasound Every 1–2 years
Colonoscopy Every 2–3 years
DXA (in 
hypogonadism)
Every 2–3 years
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changes in the colon and thyroid [4]. Detailed suggestions 
for the monitoring of complications in acromegaly are 
presented in Table III.
Prognosis
Untreated acromegaly causes an average reduction in 
survival of about ten years. The risk of earlier death 
doubles in a patient with active acromegaly. The most 
common causes of death are cardiovascular complica-
tions (60%), respiratory complications (25%) and neo-
plasms (15%). A decrease in GH secretion to 2.5 µg/L 
and normalisation of IGF-1 secretion are associated with 
the restoration of life expectancy in patients [24, 28].
Conclusion
Acromegaly is a rare chronic disease caused by the over-
production of GH, usually by a pituitary tumour. Despite 
the fact that the disease leads to characteristic changes in 
the appearance and the development of multiple systemic 
complications, its diagnosis is greatly delayed. A late di-
agnosis of acromegaly contributes to the development 
of complications in the cardiovascular and respiratory 
system, and malignant neoplasms. They are responsible 
for a 30% increase in the mortality rate among non-treated 
patients compared to the general population.
An important role in improving the diagnosis of 
acromegaly within the Polish health service is played by 
general practitioners. In patients with hypertension, heart 
failure, diabetes, and arthropathy, non-specific for age, 
they should pay attention to the occurrence of somatic 
signs of acromegaly and perform a screening test for IGF-1 
concentration if the signs occur. A lack of inhibition of GH 
secretion below 0.4 µg/L in OGTT and the presence of a pi-
tuitary tumour in MR imaging confirm active acromegaly. 
It is indicated to perform these tests in reference centres 
which should also assess complications of the disease and 
establish a treatment plan.
Patients with a good prognosis related to the surgi-
cal removal of the pituitary tumour should be referred 
only to centres experienced in transsphenoidal ad-
enomectomy, after a pharmacological preparation. 
Other patients, and those who have not recovered 
after surgical treatment, should be subjected to long-
term pharmacotherapy with long-acting somatostatin 
analogues. In each case, in addition to the evaluation 
of therapeutic efficacy, the complications of acromegaly 
should be followed-up and actively treated.
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